5 assets in Pleural Cancer

Therapeutic assets addressing Pleural Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Pleural Cancer	Memorial Sloan Kettering Cancer Center	P1/2	CCC (54)
Icasp9M28Z T Cell Infusions Pleural Cancer	Memorial Sloan Kettering Cancer Center	P1/2	CCC (48)
Pembrolizumab Pleural Cancer	Memorial Sloan Kettering Cancer Center	P1/2	CCC (48)
Fapi-46 Pleural Cancer	Jonsson Comprehensive Cancer Center	P1	CC (43)
mt027 Pleural Cancer	Suzhou Maximum Bio-tech Co., Ltd.	P1	NR ()